Objective: Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multiagent chemotherapy is not an option. The objective of this study was to describe real-world outcomes with BV in patients with rrHL considered ASCT ineligible or who refuse ASCT.
| INTRODUCTION
A high proportion of patients with Hodgkin lymphoma (HL) respond to front-line chemotherapy regimens but depending on initial therapy; however, up to 20% of patients progress or relapse after initial treatment. [1] [2] [3] [4] The current standard of practice in these patients is salvage chemotherapy followed by high-dose chemotherapy and ASCT, which has been shown to prolong progression-free survival (PFS). [5] [6] [7] However, a relevant proportion of patients who have chemorefractory disease, advanced age, or significant medical comorbidities are not considered candidates for ASCT, or do not undergo ASCT due to patient preference, and therefore have a poor prognosis. 8 Until recently, treatment options for these patients have been limited to palliative approaches including gemcitabine-based chemotherapy, bendamustine, or local radiotherapy for symptom control. 5 Brentuximab vedotin (BV) is an antibody-drug conjugate targeted to CD30, a cell surface marker that is highly expressed on malignant HL cells, 9, 10 with limited expression in healthy tissue and on resting leukocytes, 11, 12 making it a rational target for antibody-based therapies. BV is licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following ASCT or following at least two prior therapies when ASCT or multiagent chemotherapy is not a treatment option.
Previous prospective studies of BV in ASCT-ineligible patients include a posthoc analysis of a phase 1 trial, 8 and a single-arm, phase 4 trial. 13 Small retrospective studies, [14] [15] [16] 
| PATIENTS AND METHODS
This was a retrospective medical chart review study that enrolled pa- Patient demographics, clinical characteristics, and treatment characteristics were described. Clinical outcomes included best response to treatment, progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Given the retrospective nature of the study, no assessment of causality was made for AEs. Outcomes were primarily descriptive and reported in the full study population and by country. PFS and OS were analyzed using the non-parametric Kaplan-Meier method, where patients were censored at their last available follow-up. A post hoc analysis comparing best response to therapy on BV compared to the line of therapy received just prior to BV was conducted using Chi-square tests to explore the relative effectiveness of BV compared to other regimens while having each patient serve as his or her own control.
| RESULTS
A total of 136 patients (78 in Germany and 58 in the United Kingdom)
were included in this study. The median duration of follow-up was 10.9 months (range, 0.4-47.0 months) from initiation of BV. Study investigators represented primarily hospital-based practice (90% in Germany, 100% in the United Kingdom) and were mostly affiliated with academic/ teaching hospitals (70% in Germany, 60% in the United Kingdom).
Across both countries, the mean age at first HL diagnosis was 66.7 years and 40% of patients had bulky disease at diagnosis (Table 1) . At first diagnosis, patients in Germany appeared to be older, have more often advanced disease, worse ECOG status, and were more likely to have bulky disease compared with patients in the United
Kingdom. According to treating physicians, the most common reasons for ASCT ineligibility were comorbidities (73.5%) and age (56.6%; had documented use of BV as the first line of therapy after their initial relapse. Of note, the study investigators confirmed that all patients met study eligibility criteria, and thus, it is possible that radiotherapy was counted as a line of therapy. The remaining patients received BV as indicated for the second or later postrelapse line of therapy. At the relapse treated with BV, 54% of patients had stage III or IV disease, 9.6%
had bulky disease, and 61.0% had an ECOG status ≥2 (Table 2 ).
| Efficacy outcomes
Patients received a median of 8 cycles of BV (range, 6-15 cycles). The overall response rate was 74.3% of patients, and 34.6% of patients achieved a complete response to BV across the study population from both countries (Table 3) . ORR with BV and the preceding line of therapy were not significantly different. One patient in Germany 
| Adverse events
The most common adverse events reported during treatment with BV included leukopenia, anemia, and diarrhea (Table 4 ). The documented incidence of peripheral neuropathy during BV treatment was 9.6%, of which 92.3% of cases were non-serious.
| DISCUSSION
This multinational rrHL population receiving BV in routine clinical care is different from those previously published in being older T A B L E 1 Characteristics of ASCTineligible patients with rrHL at first diagnosis (median age 67 years vs 38 and 45 years in previous studies) and less likely to be ASCT ineligible due to refractory disease (12% vs 64%
and 75% in previous studies). In addition, our study also included a small proportion of patients who elected not to undergo ASCT. It thereby better reflects the real-world challenges of treating elderly patients or those with significant comorbidities. Nevertheless, the ORR (74.3%) was similar to previous retrospective studies (71% and 75%), 14, 15 while the ORR in previous prospective studies was lower (30% and 50%). 8, 13 Lower response rates in the BV phase 1 study might partially be due to low doses applied during dose escalation, while the difference in the phase 4 study might be explained by the utilization of an independent review facility to assess outcomes as opposed to the investigator's clinical judgment. The median OS in our study was 17.1 months compared with 40.1 months in the pivotal BV phase II study, likely reflecting differences in median age (66.7 vs 31 years), prior treatments (no-ASCT vs ASCT), and comorbidities of the studied population. 18 Nevertheless, 64.7% of deaths were HL-related potentially indicative of poorer disease control in an ASCT-naïve population.
Despite their advanced age and comorbidities of patients in this sample, peripheral neuropathy was reported less frequently than in patients enrolled in the pivotal BV trial (9.6% vs 42%) 19 and in the Named Patient Program (20%). 17 However, given the retrospective nature of the study and data derived from real-world patient files rather than study documentation, it is possible and indeed likely that such
AEs were under-reported.
Of note, the results of the study highlight differences in the stan- be accomplished with secondary data. Moreover, study data were collected by physician investigators, further contributing to the overall study strength and accuracy of the data. The sample size in this multicenter study of 136 patients from across two European countries is also larger than previously published studies. The retrospective nature of the study, however, means that the data collected were T A B L E 4 Adverse events of any grade occurring during treatment with BV of the 136 patients in the study received BV outside its original indication after only one prior line of treatment, which may be due to the application of different criteria for identifying lines of therapy.
In conclusion, the results of this study in a population of advanced age with relevant comorbidities are encouraging and suggest that BV demonstrates real-world clinical effectiveness for patients with rrHL who are ineligible for ASCT. BV would appear to be a useful treatment option in this population where there is a great clinical need with limited treatment options and currently poor outcomes. Further comparative effectiveness data are needed to evaluate these outcomes relative to other therapeutic interventions.
